注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Theratechnologies Inc是一家总部位于加拿大的生物制药公司。该公司致力于开发和商业化治疗方法,以满足未满足的医疗需求。该公司将两种人体免疫缺陷病毒(HIV)药物商业化,并在非酒精性脂肪性肝炎(NASH)、肿瘤和HIV方面开展研究项目。其药物包括Trogarzo、EGRIFTA SV和EGRIFTA。Trogarzo(ibalizumab uiyk)是一种单克隆抗体,可与集群差异4(CD4)T细胞受体的结构域2结合。在美国,Trogarzo被开发用于治疗HIV-1感染。EGRIFTA SV(注射用特斯莫林)和EGRIFTA-是为减少人体免疫缺陷病毒(HIV)感染的脂肪营养不良患者腹部多余脂肪而开发的。其肿瘤学管道包括TH1902和TH1904。其非酒精性脂肪肝(NAFLD)管道包括Tesamorelin F8。TH1902正在一期临床试验中评估。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Roger Guillemin | - | - | Member of the Scientific Advisory Board |
David Clemmons | - | - | Member of the Scientific Advisory Board |
Peter Reiss | - | - | Member of the Scientific Advisory Board |
Steven Grinspoon | - | - | Member of the Scientific Advisory Board |
Julian Falutz | - | - | Member of the Scientific Advisory Board |
George R. Merriam | - | - | Member of the Scientific Advisory Board |
Dawn A. Svoronos | 70 | 2013 | Independent Chair of the Board |
Gerald A. Lacoste | 79 | 2006 | Independent Director |
Paul Lévesque | 59 | 2020 | President, CEO & Director |
Dale MacCandlish-Weil | 67 | 2017 | Independent Director |
Joseph P. Arena | 68 | 2021 | Independent Director |
Andrew T. Molson | 55 | 2020 | Independent Director |
Frank A. Holler | 67 | 2021 | Independent Director |
Jordan Zwick | 37 | 2024 | Independent Director |
Elina Tea | 47 | 2024 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核